To date, four HDAC inhibitors have been approved as second line treatment for relapsed peripheral T-cell lymphoma (PTCL) and/or cutaneous T-cell lymphoma (CTCL) and multiple myeloma by the FDA [109]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.